A mong myriad cardiac and noncardiac changes that occur during the evolution of heart failure with preserved ejection fraction (HFpEF), myocardial interstitial disease (MID) from myocardial fibrosis (MF) may precede the clinical diagnosis of HFpEF and be associated with higher disease severity and worse subsequent outcomes. The cells and secretomes involved in MF might therefore represent promising therapeutic targets specific to the heart, especially during the evolution of HFpEF, from being "at risk" for HFpEFmanifest by elevated brain-type natriuretic peptide (BNP) levels-to clinical diagnosis of HFpEF. Myocardial fibrosis indicates interstitial expansion from excess collagen and represents the most common form of MID, but misfolded light chain or transthyretin protein in cardiac amyloidosis (CA) represents a less common, more extreme form of MID, potentially confounding HFpEF studies because CA can be challenging to diagnose. Myocardial fibrosis can affect microvascular function, mechanical function, electrical function, and myocyte energetics, 1 reflecting cardiomyocyte-extracellular matrix interactions beyond the interstitium. 2 These interactions include (1) capillary rarefaction and perivascular fibrosis 3 limiting perfusion reserve, 4-6 (2) myocardial stiffening 7,8 from titin and collagen expansion with increased cross-linking in MF leading to systolic and diastolic dysfunction 6,9-11 and increased filling pressures, 7 (3) impaired electrical conduction from disarray in the collagen network architecture predisposing to reentrant arrhythmia and sudden death, 12,13 and (4) likely impaired cardiomyocyte or mitochondrial energetics if interposing excess collagen isolates cardiomyocytes from capillaries in the setting of decreased perfusion reserve and myocardial stiffening.
14 Beyond these deleterious MF-cardiomyocyte interactions, further evidence supports MF as a promising therapeutic target during the evolution of HFpEF: MF may be prevalent, 15 strongly associated with outcomes in general cohorts, [15] [16] [17] [18] and reversible. 4,9,10,19-21 Yet, HFpEF remains an incompletely understood, etiologically heterogeneous prevalent syndrome in need of efficacious therapies to reduce mortality and hospitalization. Trials of HFpEF using conventional, modestly "antifibrotic" renin-angiotensinaldosterone system inhibitors 2,14 have mostly had neutral results but have been confounded by substantial methodologic issues, such as the inadvertent inclusion of patients with CA whose condition would not respond to antifibrotic therapy. Targeting specific phenotypes in the spectrum of HFpEF with specific therapies instead of a "one-size-fits-all" treatment approach may become increasingly important to address unmet needs.
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To investigate MF during the apparent evolution of HFpEF, we enrolled 1174 consecutive patients referred for cardiovascular magnetic resonance (CMR) with preserved systolic function in a single-center observational study. We quantified MF severity using robust extracellular volume (ECV) CMR measures, and grouped patients according to HFpEF categories. 15 We identified clinical HFpEF if patients' physicians documented heart failure signs and symptoms.
In the absence of clinical HFpEF, we identified those "at risk" for HFpEF by elevated BNP levels because BNP specifies cardiac dysfunction and is robustly associated with adverse outcomes. We hypothesized that their extent of MF and clinical course would resemble that of patients with clinically diagnosed HFpEF. Thus, after excluding the small but important subset of HFpEF patients with evident CA among those with HFpEF or at risk for HFpEF, we examined the association of MF with baseline disease severity measures of hemodynamic stress, that is, BNP levels, and subsequent outcomes, namely, the combined end point of hospitalization for heart failure and all-cause mortality.
Methods

Participants
After approval by the UPMC institutional review board , we recruited 2316 consecutive adult patients referred to the UPMC CMR Center at time of clinical CMR from June 1, 2010, to September 17, 2015, observed until December 14, 2015. Inclusion criteria were written informed consent and completion of a gadolinium contrast-enhanced CMR. Exclusion criteria included (1) hypertrophic cardiomyopathy (n = 221), (2) stress-induced cardiomyopathy (n = 14), (3) adult congenital heart disease (n = 339), (4) inadequate image quality (eg, coil malfunction [n = 4]), and (5) individuals with siderosis (n = 5) or Fabry disease (n = 3). Because the goal of this work was to examine those with preserved systolic function, we also excluded participants with overt systolic dysfunction determined by CMR, defined as left ventricular ejection fraction less than 50% (n = 556). The final cohort included 1174 patients.
Data Elements
Data elements have been described previously. 15 Data were managed using REDCap (Research Electronic Data Capture) hosted at the University of Pittsburgh. Baseline comorbidity data at the time of CMR were determined from the medical record. Investigators classified race. We divided the cohort into 3 main categories: (1) clinical HFpEF, (2) no clinical HFpEF but at risk for HFpEF given elevated BNP levels (>100 pg/mL; to convert to nanograms
Key Points
Question Does myocardial fibrosis occur during the evolution of heart failure with preserved ejection fraction (HFpEF) and is it associated with disease severity and outcome in those with HFpEF or at risk for HFpEF?
Findings In this cohort study of 410 patients at risk for or with a diagnosis of HFpEF, myocardial fibrosis quantified by extracellular volume was associated with baseline brain-type natriuretic peptide level (disease severity surrogate) in linear regression models, and outcomes of heart failure hospitalization or death in Cox models.
Meaning Among myriad changes in evolving HFpEF, myocardial fibrosis is prevalent and was associated with disease severity and adverse outcomes, so whether the cells and secretomes mediating myocardial fibrosis represent therapeutic targets in HFpEF warrants further evaluation. 
CMR Scans
Cine CMR | Patients received clinical CMR scans from a 1.5-T scanner (Magnetom Espree, Siemens Medical Solutions). Examinations included standard cine imaging with steady-state free precession as we have described previously. 24,25 Left ventricular volumes, mass, and ejection fraction were measured by experienced readers from short-axis stacks of cine frames that covered the ventricles (6-mm slice, 4-mm gap).
Late Gadolinium Enhancement | Late gadolinium enhancement (LGE) imaging was performed 10 minutes after a 0.2-mmol/kg intravenous gadoteridol bolus (Prohance, Bracco Diagnostics) with a motion-corrected phase-sensitive inversion recovery pulse sequence 25 matching the cine imaging planes. The extent of myocardial infarction and LGE was assessed visually in terms of the extent of LGE (none, <25%, 26%-50%, 51%-75%, >75%), rendering 5 categories for each of the 17 segments to compute extent of LGE.
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We identified CA according to the clinical report, based on prominent diffuse LGE in a nonischemic pattern with other associated features (eg, poor annular motion, diffuse subendocardial enhancement, and increased myocardial thickness).
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Most patients with CA had ancillary biopsy data supporting the CA diagnoses. After CA was excluded, those with elevated ECV were assumed to have MF.
Quantification of Myocardial Fibrosis With the ECV
We used reproducible 27 and validated ECV measures after a gadolinium bolus described previously. 16 , 17 We did not exclude foci of nonischemic scar on LGE images (ie, atypical of myocardial infarction) from ECV measures acquired in noninfarcted myocardium, 16,17,28 which would bias ECV measures. We measured the middle third of myocardium to avoid partial-volume effects. We quantified MF with ECV 28 defined as ECV = λ ×
(1 − hematocrit), where λ = (ΔR1 myocardium )/(ΔR1 bloodpool ) before and after administration of gadolinium contrast (where R1 = 1/T1) from basal and mid-ventricular short-axis slices in noninfarcted myocardium as described previously. Patients with CA (n = 19) were excluded from all multivariable analyses. Linear regression models were used to assess associations with log-transformed BNP levels ignoring 13 participants with missing BNP. Survival analyses examined a combined end point of time to either first HHF or death (all-cause mortality) because ECV shows similar relationships when each event is modeled separately. 15 Kaplan-Meier curves used the log-rank test with ECV categorized arbitrarily in 5% intervals to demonstrate doseresponse relationships. Cox regression analysis was used to examine associations between MF and outcomes in those with clinically diagnosed HFpEF and those at risk for HFpEF (BNP > 100 pg/mL) because these groups were suspected to have similar risk profiles and MF burden. Further analyses were limited to only the cohort with clinically diagnosed HFpEF. Extracellular volume was expressed as a continuous variable (percentage) and reported as a 5% hazard ratio increment to scale the hazard ratio to a clinically meaningful interval. Similarly, all continuous variables in regression models were scaled to clinically meaningful intervals. To benchmark ECV against other clinically important variables, we compared Cox regression χ 2 values.
Given limited numbers of events, we created 2 principal parsimonious Cox regression models acknowledging alternate valid methodologies. The first "clinical" model attempted thoughtful variable selection informed by clinical judgement, prior literature, and inspection of univariable models, specifically selecting variables representing separate independent disease processes distinct from MF that also may relate to outcomes. The second model used automated "stepwise selection" from the pool of available variables using a typical threshold of P = .10 to enter and remain in the model. To conserve degrees of freedom while maximizing risk adjustment, we constrained the number of covariates to minimize overfitting and stratified all multivariable Cox models by "risk marker" frailty variables such as hospitalization status and hematocrit (categorized as quartiles) that do not illuminate etiology in HFpEF. In analysis stimulated by clinical interest, these models included BNP as a covariate, ignoring the lack of independence between BNP and ECV whereby prognostic associations can be shared among nonindependent variables. We confirmed the proportional hazards assumption. Extracellular volume did not interact with myocardial infarction size, focal nonischemic LGE, or left ventricular mass index. Statistical tests were 2 sided, and P < .05 was considered significant. Statistical analyses were performed using SAS, version 9.4.
Results
Baseline Characteristics
The baseline characteristics of the patients with preserved ejection fraction (≥50%) are summarized in Association Between MF and BNP Extracellular volume measurement of MF was the variable most strongly associated with log-transformed BNP levels in the cohort of patients combining clinically diagnosed HFpEF and those at risk for HFpEF given elevated BNP values ( Table 2) . Similar ECV-BNP associations were found in only clinically diagnosed HFpEF. Significant associations between log BNP and ECV remained after adjustment in multivariable models.
Association Between MF and Outcomes
Over a median follow-up period of 1.9 years (IQR, 0.9-2.9 years), event rates were higher in either those with clinically diagnosed HFpEF (n = 24 [15.0%]) or those at risk for HFpEF given elevated BNP levels (n = 37 [14.8%]) compared with patients without HFpEF or elevated BNP (n = 26 [3.5%] ). Yet, similar to the lack of intergroup differences in ECV between those with clinically diagnosed HFpEF and those at risk for HFpEF, there were also no significant differences in the survival analyses (log-rank 0.8; P = .38) ( Table 3 and Figure 2 ). Among these patients, the actual clinical diagnosis of HFpEF was not associated with outcomes. Combining those with HFpEF or at risk for HFpEF, we observed strong associations between ECV measures of MF and outcomes ( Figure 2B and Table 3 ), where higher ECV was associated with higher event rates in a dose-response fashion. Sixty-one patients experienced events after CMR (19 HHF events and 48 deaths in which 6 patients died after HHF). The patients with CA demonstrated the highest event rates ( Figure 2B ), demonstrating their ability to confound HFpEF trials through inadvertent inclusion and justifying their exclusion from the main analysis.
Among the various indicators of myocardial disease, MF was among the cardiac variables most strongly associated with adverse outcomes in univariable Cox models and the 2 principal multivariable models (Table 3) , even when the cohort included only those with HFpEF. While the clinical diagnosis of HFpEF was not associated with outcomes after combining these 2 groups, ECV provided robust risk stratification.
When BNP was excluded as a covariate in these models (given the lack of independence observed between ECV and BNP), ECV exhibited even stronger associations in multivariable models (data not shown). Extracellular volume was associated with outcomes more strongly than log BNP based on χ 2 values in univariable models (Table 3) or when both variables were included in a Cox model (17.9 vs 7.8 among 397 patients with HFpEF or at risk for HFpEF). There was no statistical interaction (P = .47). Stepwise variable selection identified ECV as a robust risk stratifier but not BNP.
Discussion
Our data leveraging CMR to characterize patients with HFpEF generate several novel observations. First, despite the inherent heterogeneity of patients with HFpEF, our results emphasize the potential for abnormalities located specifically in the myocardium-as opposed to the periphery-to mediate disease severity and outcomes in HFpEF. Second, patients with HFpEF or at risk for HFpEF demonstrated high prevalence of elevated BNP and similarly worse prognosis and similarly higher prevalence and extent of MF compared with patients without HFpEF, who fared significantly better. These data imply but do not prove that during the apparent evolution of HFpEF, MF might precede the clinical diagnosis of HFpEF. Indeed, once elevated BNP appeared, the actual clinical diagnosis of HFpEF was not associated with significant differences in either MF or subsequent prognosis among those with HF or at risk for HFpEF, perhaps reflecting the clinical challenge of establishing the HFpEF diagnosis and distinguishing from other comorbidity. Third, MF was strongly associated with (1) myocardial disease severity measured by BNP, and (2) outcomes such as subsequent death and hospitalization for heart failure in proportion to MF severity. In fact, ECV measures provided unprecedented risk stratification in those with HFpEF or those at risk in whom event-free survival curves varied widely according to ECV strata, and we observed a doseresponse relationship between MF and outcome, even after adjustment for several important variables. Despite the "neutral" results of the TOPCAT trial, in which significant results were obtained only in secondary end point or post hoc analyses, the strength of associations between MF Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CMR, cardiovascular magnetic resonance; ECV, extracellular volume; LGE, late gadolinium enhancement. a There were 13 excluded individuals in whom BNP was not measured. The t values indicate the univariable strength of association between a given variable and log BNP, and the R 2 values describe the proportion of variation in log BNP explained by the given model. The β values with standard error describe the coefficients in the model. Continuous variables were scaled to clinically meaningful increments that increase β coefficients but do not affect t values. The R 2 for the multivariable model was 0.28. ; (2) inadvertent inclusion of patients with unsuspected CA (challenging to diagnose without CMR or bone scintigraphy) whose condition would not respond to spironolactone; and (3) heterogeneous patient populations, without adequate prevalence of MF or even HFpEF, diluting therapeutic responses in the overall study. Resolving these issues requires further study, including studying the degree to which therapies regress MF.
Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction
Considerable data emphasize the potential for cardiomyocyte-extracellular matrix interactions in MID leading to organ dysfunction and ultimately adverse outcomes. There is biologic precedence in other organs (eg, lung, kidney, liver) where interstitial disease leads to organ dysfunction and vulnerability. Elegant work highlights the etiologic potential of MF in MID as well as its reversibility in animals and humans with resultant improvement in cardiac function.
4,7,9,10,19,20,29 Cardiac amyloidosis exemplifies well the relationship between MID, disease severity, and outcomes, because this group had the highest ECV, high BNP levels, and the worst outcomes. In HFpEF trials, optimal screening for exclusion of patients with CA, and optimal identification of MF where CMR is not available, for example, with biomarker panels, requires further investigation. Our work builds on a smaller study by Duca et al 30 that also suggested a potential relationship between MF and outcomes. Now, our larger data set emphasizes MF as a potential mediator of disease, possibly even preceding the clinical diagnosis of HFpEF although this issue requires further confirmation. Myocardial fibrosis prevalence and its associations with outcomes likely vary across cohorts, which emphasizes the need for personalized medicine: treat MF in those likely to have it.
Limitations
Our study has limitations. First, associations in single-center observational data do not establish causality and could represent unmeasured confounders perhaps related to referral biases. We did not adjust for the Seattle Heart Failure Model, Heart Failure Survival Score, or Medicare readmission models, but we are uncertain whether these scores derived mostly from those with reduced ejection fraction generalize to HFpEF with adequate discrimination and calibration. Still, we used various multivariable models including many of the same covariates in these risk scores and attempted to maximize risk adjustment with diverse covariates while avoiding overfitting to minimize this possibility. We also attempted to minimize exclusions and maximize the size of the cohort to maxi- 
Conclusions
Our data add to the growing literature promoting MF as a promising therapeutic target in HFpEF trials. Myocardial fibrosis seemed to precede the clinical diagnosis of HFpEF. Extracellular volume MF measures were strongly associated with disease severity and vulnerability to adverse outcomes such as death and HHF in those with HFpEF or at risk for HFpEF manifest by elevated BNP levels. Cardiovascular magnetic resonance detected a small but important CA subgroup with high event rates that could confound trials given its potential to escape clinical recognition. Given the biologic plausibility of MF mediating adverse outcomes, the issue of whether the cells and secretomes underlying MF represent potential therapeutic targets for future HFpEF trials warrants further evaluation.
